Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место каптоприла в терапии сердечно-сосудистых заболеваний
Место каптоприла в терапии сердечно-сосудистых заболеваний
Задионченко В.С., Ялымов А.А., Шехян Г.Г. и др. Место каптоприла в терапии сердечно-сосудистых заболеваний. Справочник поликлинического врача. 2017; 1: 70–75.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлено описание ингибитора ангиотензинпревращающего фермента каптоприла. Дана характеристика фармакокинетики препарата и механизмы его органопротективных эффектов. Представлены результаты многоцентровых рандомизированных исследований каптоприла у больных артериальной гипертонией, нефропатией на фоне сахарного диабета, с инфарктом миокарда и сердечной недостаточностью. На основании клинических исследований доказана высокая эффективность каптоприла в терапии сердечно-сосудистых заболеваний.
Ключевые слова: ингибитор ангиотензинпревращающего фермента, липофильные ингибиторы ангиотензинпревращающего фермента, сульфгидрильная группа, каптоприл, артериальная гипертония, гипертонический криз, нефропатия, сердечная недостаточность, инфаркт миокарда, ремоделирование миокарда.
Key words: angiotensin-converting enzyme inhibitor, lipophilic angiotensin-converting enzyme inhibitors, sulfhydryl group, captopril, arterial hypertension, hypertensive crisis, nephropathy, heart failure, myocardial infarction, myocardial remodeling.
Ключевые слова: ингибитор ангиотензинпревращающего фермента, липофильные ингибиторы ангиотензинпревращающего фермента, сульфгидрильная группа, каптоприл, артериальная гипертония, гипертонический криз, нефропатия, сердечная недостаточность, инфаркт миокарда, ремоделирование миокарда.
________________________________________________
Key words: angiotensin-converting enzyme inhibitor, lipophilic angiotensin-converting enzyme inhibitors, sulfhydryl group, captopril, arterial hypertension, hypertensive crisis, nephropathy, heart failure, myocardial infarction, myocardial remodeling.
Полный текст
Список литературы
1. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77.
2. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
3. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
6. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
2. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
3. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
6. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
2. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
3. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
6. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
________________________________________________
2. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute MI. Lancet 1995; 345: 669–85.
3. Chinese Cardiac Study (CCS-1) Collaborative Group. Oral captopril versus placebo among 14,962 patients with suspected acute MI: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Chin Med J 1997; 110: 834–8.
4. Hansson L, Lindholm LH et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
5. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
6. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.
7. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360 (9335): 752–60.
8. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
Авторы
В.С.Задионченко*1, А.А.Ялымов1, Г.Г.Шехян1, А.М.Щикота1, Н.Ю.Тимофеева1, С.А.Терпигорев2, Т.Г.Кабанова2, Е.Б.Широкова2
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского». 129110, Россия, Москва, ул. Щепкина, д. 61/2
*z7vladimir@bk.ru
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 M.F.Vladimirskiy Moscow regional research clinical institute. 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
*z7vladimir@bk.ru
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России. 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
2 ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского». 129110, Россия, Москва, ул. Щепкина, д. 61/2
*z7vladimir@bk.ru
________________________________________________
1 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
2 M.F.Vladimirskiy Moscow regional research clinical institute. 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2
*z7vladimir@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.